How to buy Zoetis stock (ZTS)

Zoetis is a drug manufacturers - specialty & generic business based in the US. Zoetis shares (ZTS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $178.18 – a decrease of 0.37% over the previous week. Zoetis employs 14,100 staff and has a trailing 12-month revenue of around $9.2 billion.

Our top picks for where to buy Zoetis stock

Buy Zoetis stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Zoetis stock price (NYSE: ZTS)

Use our graph to track the performance of ZTS stocks over time.

Zoetis shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$178.18
52-week range	$144.11 - $199.86
50-day moving average more info button	$181.71
200-day moving average more info button	$177.40
Wall St. target price	$214.22
PE ratio more info button	33.3026
Dividend yield more info button	$1.671 (0.98%)
Earnings per share (TTM) more info button	$5.32

Is it a good time to buy Zoetis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zoetis price performance over time

Historical closes compared with the close of $170.79 from 2024-12-17

1 week (2024-12-11)	-3.60%
1 month (2024-11-19)	-2.72%
3 months (2024-09-18)	-13.08%
6 months (2024-06-18)	0.67%

1 year (2023-12-18)	-13.18%
2 years (2022-12-16)	20.49%
3 years (2021-12-17)	228.2403
5 years (2019-12-18)	39.62%

Is Zoetis stock undervalued or overvalued?

Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zoetis's P/E ratio

Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Zoetis shares trade at around 33x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Zoetis's PEG ratio

Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.7557. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Zoetis's EBITDA

Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.8 billion.

The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.

Zoetis financials

Revenue TTM	$9.2 billion
Operating margin TTM	38.53%
Gross profit TTM	$5.6 billion
Return on assets TTM	14.66%
Return on equity TTM	47.3%
Profit margin	26.55%
Book value	$11.59
Market Capitalization more info button	$79.9 billion

TTM: trailing 12 months

Zoetis's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Zoetis's total ESG risk score

Total ESG risk: 28.6

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 12/31/2018) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Zoetis's environmental score

Environmental score: 2.72/100

Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Zoetis's social score

Social score: 13/100

Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Zoetis's governance score

Governance score: 8.87/100

Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Zoetis's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Zoetis Inc was last rated for ESG on: 2019-01-01.

Total ESG score	28.6
Total ESG percentile	49.38
Environmental score	2.72
Environmental score percentile	1
Social score	13
Social score percentile	1
Governance score	8.87
Governance score percentile	1
Level of controversy	1

Zoetis share dividends

Dividend payout ratio: 30% of net profits

Recently Zoetis has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $1.671 per share.

While Zoetis's payout ratio might seem fairly standard, it's worth remembering that Zoetis may be investing much of the rest of its net profits in future growth.

Zoetis's most recent dividend payout was on 2 December 2024. The latest dividend was paid out to all shareholders who bought their shares by 30 October 2024 (the "ex-dividend date").

Zoetis share price volatility

Over the last 12 months, Zoetis's shares have ranged in value from as little as $144.1149 up to $199.8564. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.896. This would suggest that Zoetis's shares are less volatile than average (for this exchange).

Zoetis overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc.

Frequently asked questions

null
What percentage of Zoetis is owned by insiders or institutions?
Currently 0.203% of Zoetis shares are held by insiders and 95.818% by institutions. How many people work for Zoetis?
Latest data suggests 14,100 work at Zoetis. When does the fiscal year end for Zoetis?
Zoetis's fiscal year ends in December. Where is Zoetis based?
Zoetis's address is: 10 Sylvan Way, Parsippany, NJ, United States, 07054 What is Zoetis's ISIN number?
Zoetis's international securities identification number is: US98978V1035 What is Zoetis's CUSIP number?
Zoetis's Committee on Uniform Securities Identification Procedures number is: 98978V103